Abstract
Stem cell transplantation is an effective treatment for anemia associated with stem cell disorders such as severe aplastic anemia, myelodysplastic syndrome. Long-term survival rates after transplantation for those diseases range from less than 40% to more than 80%. The rates are significantly affected by recipient's age, HLA disparity between donor and recipient, sources of stem cells, and disease status. Results are best in younger patients transplanted with bone marrow from HLA-identical sibling at the early course of the diseases. The decision of whether and at what point to proceed to transplantation should be made early after diagnosis, based upon the consideration of a survival rate with reasonable quality of life expected with transplantation and other therapeutic approaches.
| Original language | English |
|---|---|
| Pages (from-to) | 575-583 |
| Number of pages | 9 |
| Journal | Nippon rinsho. Japanese journal of clinical medicine |
| Volume | 66 |
| Issue number | 3 |
| Publication status | Published - 2008 Mar |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Allogeneic stem cell transplantation for severe aplastic anemia and myelodysplasia. / Okamoto, Shinichiro.
In: Nippon rinsho. Japanese journal of clinical medicine, Vol. 66, No. 3, 03.2008, p. 575-583.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Allogeneic stem cell transplantation for severe aplastic anemia and myelodysplasia
AU - Okamoto, Shinichiro
PY - 2008/3
Y1 - 2008/3
N2 - Stem cell transplantation is an effective treatment for anemia associated with stem cell disorders such as severe aplastic anemia, myelodysplastic syndrome. Long-term survival rates after transplantation for those diseases range from less than 40% to more than 80%. The rates are significantly affected by recipient's age, HLA disparity between donor and recipient, sources of stem cells, and disease status. Results are best in younger patients transplanted with bone marrow from HLA-identical sibling at the early course of the diseases. The decision of whether and at what point to proceed to transplantation should be made early after diagnosis, based upon the consideration of a survival rate with reasonable quality of life expected with transplantation and other therapeutic approaches.
AB - Stem cell transplantation is an effective treatment for anemia associated with stem cell disorders such as severe aplastic anemia, myelodysplastic syndrome. Long-term survival rates after transplantation for those diseases range from less than 40% to more than 80%. The rates are significantly affected by recipient's age, HLA disparity between donor and recipient, sources of stem cells, and disease status. Results are best in younger patients transplanted with bone marrow from HLA-identical sibling at the early course of the diseases. The decision of whether and at what point to proceed to transplantation should be made early after diagnosis, based upon the consideration of a survival rate with reasonable quality of life expected with transplantation and other therapeutic approaches.
UR - http://www.scopus.com/inward/record.url?scp=42449102709&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=42449102709&partnerID=8YFLogxK
M3 - Article
C2 - 18326329
AN - SCOPUS:42449102709
VL - 66
SP - 575
EP - 583
JO - Nihon rinsho. Japanese journal of clinical medicine
JF - Nihon rinsho. Japanese journal of clinical medicine
SN - 0047-1852
IS - 3
ER -